Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

ACC/AHA vs ESC/ESH guideline: Assessing impact on hypertension prevalence, treatment

23 Jun 2019
The American Heart Association has lowered the value for diagnosing hypertension to 130/80 from the previous 140/90.

Implementing the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline over that of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) will give rise to a substantial increase in the prevalence of hypertension, as well as the number of adults who should receive medication, according to a study.

“There is room for improvement in lifestyles and cardioprotective treatment in individuals with blood pressure (BP) of 130–139/80–89 mm Hg whether they are called hypertensive (ACC/AHA) or not (ESC/ESH),” the authors said.

Hypertension prevalence using the ACC/AHA guidelines was 46.9 percent (95 percent CI, 46.0–47.8 percent), while that of the ESC/ESH guideline was 33.1 percent (32.2–33.9 percent); antihypertensive medication was recommended for 33.5 percent (32.7–34.3 percent) and 37.2 percent (36.2–38.1 percent) of adults, respectively.

Using the ACC/AHA vs the ESC/ESH guideline resulted in 5.3 more million hypertensive patients and 1.4 more million candidates for medication (for a 40-million adults’ country).

Some cardiometabolic goals (eg, nonsmoking, reduced salt consumption, low-density lipoprotein cholesterol, lifestyle medical advice and treatment with renin–angiotensin-system blockers) were achieved less frequently by participants who were hypertensive under the ACC-AHA compared to those who were hypertensive under the ESC/ESH guideline.

“We suggest that clinical-practice guidelines should consider the public health and costs implications, and not only the evidence on effectiveness and cost-effectiveness, of their recommendations,” the authors said.

In this study, data from a national survey on 12,074 individuals (aged 18 years) representative of the population in Spain were analysed. Standardized procedures were used to measure BP.

“Unlike the 2018 ESC/ESH guideline, the 2017 ACC/AHA guideline has recommended a shift in hypertension definition from BP 140/90–130/80 mm Hg. Further, they proposed somewhat different indications for antihypertensive medication,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.